CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM089479
Első szerző:Balogh Boglárka (belgyógyász)
Cím:Gut barrier failure : a piece in the puzzle of acute-on chronic liver failure syndrome development? / Boglarka Balogh, Zsuzsa Vitalis, Tamas Tornai, Istvan Tornai, David Tornai, Aniko Csillag, Peter Antal-Szalmas, Maria Papp
Dátum:2020
Megjegyzések:Introduction: Intestinal barrier dysfunction induced inflammation facilitates pathologic bacterial translocation (BT) which is a characteristic feature of liver cirrhosis (LC). BT plays a crucial role in the progression of LC leading to spontaneous bacterial peritonitis (SBP), bacteraemia and induction of proinflammatory responses causing various organ damages. Therefore, the serological hallmarksof gut barrier dysfunction in cirrhosis are able to predict the accelerated progression of liver disease. Methods: In a cohort of patients with decompensated cirrhosis (n=135) prospectively followed-up for 1 year and in healthy controls (HC) (n=50) the serological markers of functional/structural gut damage (intestinal-fatty acid binding protein, I-FABP), BT (Endotoxin core antibody, EndoCab IgA) and mucosal immune response (secretory IgA, Immunoglobulin free light chain (Ig FLC) kappa and lambda,) were investigated by means of ELISA. Results: Comparing the LC to HC group the serum concentration of all investigated markers weresignificantly higher in cirrhotic patients, although they did not show any association with the disease severity. Investigating the role of the serological markers in the development of ACLF we found that significance of the serum level of Ig FLC kappa in ACLF prediction is comparable to AD score based on AUC values. Furthermore, the ACLF rate was lower in patients with low serum concentration of Ig FLC kappa compared to the group with high serum concentration of this molecule. Conclusions: Ig FLC kappa can be a usable marker in the serological panel for the prediction of ACLF development in acute decompensated cirrhotic patients. Acknowledgements: EFOP 3.6.2-16-2017-00006 (LIVE LONGER).
Tárgyszavak:Orvostudományok Klinikai orvostudományok előadáskivonat
könyvrészlet
Megjelenés:Proceedings of the EFOP-3.6.2-16-2017-00006 (LIVE LONGER) project /Ed. Rakonczay Zoltán, Kiss Lóránd. - p. 62. -
További szerzők:Vitális Zsuzsanna (1963-) (belgyógyász, gasztroenterológus) Tornai Tamás István (1984-) (belgyógyász) Tornai István (1954-) (belgyógyász, gasztroenterológus) Tornai Dávid (1989-) (hepatológia, biomarker kutatás) Csillag Anikó (1979-) (immunológus, biológus, angol-magyar szakfordító) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:EFOP-3.6.2-16-2017-00006
EFOP
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM089481
Első szerző:Csillag Anikó (immunológus, biológus, angol-magyar szakfordító)
Cím:Filamentosus-actin related molecules : are they serologic hallmark of overwhelming damage-associated molecular patterns (DAMPs) in acute decompensation? / Aniko Csillag, Zsuzsa Vitalis, Tamas Tornai, Istvan Tornai, David Tornai, Boglarka Balogh, Peter Antal-Szalmas, Maria Papp
Dátum:2020
Megjegyzések:Introduction: The actin cytoskeleton has a fundamental function in cellular motility, integrity, structure and signaling mechanisms. In acute decompensated liver cirrhosis large quantities of filamentous actin (F-actin) as a danger signal is released from damaged and necrotic hepatic cells. Recently it also has been demonstrated that the presence of IgA type anti-F-actin antibodies is associated with the disease severity, unfavorable disease outcome and intestinal damage, as well. Thus, we hypothesized that the actin-scavenging system molecules in acute decompensation are able to predict the accelerated progression of liver disease. Methods: In a cohort of patients with decompensated cirrhosis (n=135) prospectively followed-up for 1 year and in healthy controls (HC, n=50) the serum levels of gelsolin and anti-F-actin IgA were investigated by means of ELISA. Results: Serum gelsolin levels were significantly higher in patients with acute decompensated liver cirrhosis (LC-AD) compared to healthy controls (HCONT) (p<0.0001). The frequency of anti-F-actin positivity was 65.4% (n=83/127) in LC-AD group (cut off: 25 U/mL). Our results demonstrated that in LC-AD group the serum gelsolin levels did not show correlation with the different disease severity, the presence of bacterial infection or renal failure at inclusion, similarly to the presence or absence of anti-F-actin IgA positivity. However, high serum level of gelsolin (>87.7 ?g/mL) is associated with short term (30 days) mortality. Conclusions: High serum level of gelsolin is likely to predict short term mortality both in cirrhotic patients with or without acute-on-chronic liver failure at inclusion. Acknowledgements: EFOP 3.6.2-16-2017-00006 (LIVE LONGER).
ISBN:978-963-306-764-2
Tárgyszavak:Orvostudományok Klinikai orvostudományok előadáskivonat
könyvrészlet
Megjelenés:"PROCEEDINGS OF THE EFOP-3.6.2- 16-2017-00006 (LIVE LONGER) PROJECT" / Ed. Rakonczay Zoltán, Kiss Lóránd. - p. 63. -
További szerzők:Vitális Zsuzsanna (1963-) (belgyógyász, gasztroenterológus) Tornai Tamás István (1984-) (belgyógyász) Tornai István (1954-) (belgyógyász, gasztroenterológus) Tornai Dávid (1989-) (hepatológia, biomarker kutatás) Balogh Boglárka (1993-) (belgyógyász) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:EFOP-3.6.2-16-2017-00006
EFOP
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM089190
Első szerző:Tornai Dávid (hepatológia, biomarker kutatás)
Cím:Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality / Tornai David, Vitális Zsuzsanna, Jónás Alexa, Janka Tamás, Földi Ildikó, Tornai Tamás, Sipeki Nóra, Csillag Anikó, Balogh Boglárka, Sümegi Andrea, Földesi Róza, Papp Mária, Antal-Szalmás Péter
Dátum:2021
Megjegyzések:Background & Aims: Patients with cirrhosis are susceptible to bacterial infections (BIs) that are major causes of specific complications and mortality. However, the diagnosis of BIs can often be difficult in advanced disease stage since their symptoms may overlap with the ones of acute decompensation (AD). Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is released from monocytes/macrophages and neutrophils during activation and has been reported to correlate with activity of various inflammatory processes. We investigated its diagnostic and prognostic performance in patients with cirrhosis and BI. Methods: Sera of 269 patients were assayed for sTREM-1 by ELISA (172 outpatients and 97 patients with AD of whom 56 had BI). We investigated capacity of sTREM-1 to identify patients with BI and conducted a 90-day follow-up observational study to assess its possible association with short-term mortality. Results: sTREM-1 levels were significantly higher in patients with more severe liver disease, BI, and acute-on-chronic liver failure than in patients without these conditions. sTREM-1 had similar accuracy to CRP identifying BI [sTREM-1: AUROC (95%CI) 0.804 (0.711-0.897), p<0.0001, CRP: 0.791 (0.702-0.881) p<0.0001)] among AD patients. The combination of these two molecules and the presence of ascites into a composite score significantly increased their discriminative power (AUROC:0.878, 95%CI:0.812-0.944, p<0.0001). High sTREM-1 level (>660 pg/mL) was an independent predictor of 90-day mortality in patients with BI [HR: 2.941, (95%CI: 1.009-8.573), p=0.048] in our multivariate model. Conclusions: Use of sTREM-1 could increase the recognition of BIs in cirrhosis and help clinicians in mortality risk assessment of these patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
sTREM-1
bacterial infection
cirrhosis
acute decompensation
mortality
Megjelenés:Clinics and Research in Hepatology and Gastroenterology. - 45 : 5 (2021), p. 1-12. -
További szerzők:Vitális Zsuzsanna (1963-) (belgyógyász, gasztroenterológus) Jónás Alexa Janka Tamás Földi Ildikó (1981-) (orvos) Tornai Tamás István (1984-) (belgyógyász) Sipeki Nóra (1987-) (általános orvos) Csillag Anikó (1979-) (immunológus, biológus, angol-magyar szakfordító) Balogh Boglárka (1993-) (belgyógyász) Sümegi Andrea (1969-) (biológus) Földesi Róza (1967-) (klinikai laboratóriumi kutató, PhD hallgató) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos)
Pályázati támogatás:GINOP-2.3.2-15-2016-00048
GINOP
EFOP-3.6.1-16-2016- 00022
EFOP
EFOP- 3.6.2-16-2017-00006
EFOP
ÚNKP-19-4
ÚNKP
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1